{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:17:50Z","timestamp":1790709470854,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:33:23Z","timestamp":1785875603000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["PSMA PET in Prostate Cancer: Clinical Value, Access Challenges, and Priorities for Implementation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Fern\u00e1ndez","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G\u00f3mez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.07.007_b0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.07.007_b0010","author":"Bianchi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.007_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.04.013","article-title":"The diagnostic role of prostate-specific membrane antigen positron emission tomography for patients with rising PSA after radical prostatectomy and postoperative radiotherapy: a systematic review and meta-analysis","author":"Cannoletta","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.007_b0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","article-title":"More accurate imaging is not stage migration: time to move from \u201cHubble\u201d to \u201cWebb\u201d in hormone-sensitive prostate cancer","volume":"83","author":"Ayati","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.007_b0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2022.01.002","article-title":"Modern imaging in prostate cancer: do we treat patients, or their scans?","volume":"81","author":"Mason","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.007_b0030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment","volume":"87","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.007_b0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.007_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euros.2025.03.007","article-title":"How does routine prostate-specific membrane antigen positron emission tomography\/computed tomography modify the current management of prostate cancer? A multidisciplinary view","volume":"75","author":"Oprea-Lager","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.07.007_b0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2967\/jnumed.120.251751","article-title":"Disparities in PET imaging for prostate cancer at a tertiary Academic Medical Center","volume":"62","author":"Bucknor","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2026.07.007_b0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5489\/cuaj.9034","article-title":"Association of marginalization and PSMA-PET in prostate cancer an analysis of the Ontario PSMA-PET registry for recurrent prostate cancer","volume":"19","author":"Tan","year":"2025","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2026.07.007_b0055","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1007\/s00259-025-07323-x","article-title":"PET imaging utilization and trends in Germany: a comprehensive survey","volume":"52","author":"Holzgreve","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.07.007_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prnil.2025.09.006","article-title":"Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: trends in primary staging and biochemical recurrence","volume":"14","author":"Sandhu","year":"2026","journal-title":"Prostate Int"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:33:25Z","timestamp":1785875605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":12,"alternative-id":["S2588931126001975"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA PET in Prostate Cancer: Clinical Value, Access Challenges, and Priorities for Implementation","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}